



(12) **United States Patent**
Roseman et al.

(10) **Patent No.:** **US 9,408,838 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT**

(71) Applicant: **Gilrose Pharmaceuticals, LLC**, White Plains, NY (US)

(72) Inventors: **Bruce Roseman**, White Plains, NY (US); **Gilla Kaplan**, New York, NY (US)

(73) Assignee: **GILROSE PHARMACEUTICALS, LLC**, White Plains, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/971,325**

(22) Filed: **Dec. 16, 2015**

(65) **Prior Publication Data**

US 2016/0101095 A1 Apr. 14, 2016

Related U.S. Application Data

(60) Division of application No. 14/793,829, filed on Jul. 8, 2015, now Pat. No. 9,307,942, which is a division of application No. 14/453,014, filed on Aug. 6, 2014, now Pat. No. 9,155,502, which is a continuation-in-part of application No. 14/059,541, filed on Oct. 22, 2013, now Pat. No. 8,883,815, which is a continuation-in-part of application No. 14/112,065, filed as application No. PCT/US2012/038312 on May 17, 2012, now Pat. No. 9,089,563, said application No. 14/793,829 is a continuation-in-part of application No. 14/736,406, filed on Jun. 11, 2015, now Pat. No. 9,220,712, which is a continuation-in-part of application No. 14/112,065, filed as application No. PCT/US2012/038312 on May 17, 2012, now Pat. No. 9,089,563.

(60) Provisional application No. 61/487,847, filed on May 19, 2011.

(51) **Int. Cl.**

A61K 31/435 (2006.01)
A61K 31/4458 (2006.01)
A61B 5/00 (2006.01)
A61K 31/137 (2006.01)
A61K 45/06 (2006.01)
A61B 5/055 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/4458** (2013.01); **A61B 5/4803** (2013.01); **A61K 31/137** (2013.01); **A61K 45/06** (2013.01); **A61B 5/055** (2013.01); **A61B 5/4064** (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/4458
USPC 514/277
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,213,553 A 5/1993 Light
6,121,261 A 9/2000 Glatt et al.
8,426,423 B2 4/2013 Jordan et al.
8,883,815 B2 11/2014 Roseman
2004/0092605 A1 5/2004 Jerussi et al.
2006/0052428 A1 3/2006 Chez
2006/0161218 A1 7/2006 Danilov
2011/0178114 A1 7/2011 Aung-Din

FOREIGN PATENT DOCUMENTS

CA 2 342 432 A1 9/2002
WO WO 2010/015029 A1 2/2010

OTHER PUBLICATIONS

Leitner et al., "Gait in attention deficit hyperactivity disorder", "Effects of methylphenidate and dual tasking", Journal of Neurology, vol. 254, No. 10, pp. 1330-1338 (2007).
Reorganization after pre-and perinatal Brain Lesions; Martin Staudt; Journal of Anatomy; 2010; pp. 469-474.
New insights into the pathology of white matter tracts in cerebral palsy . . . ; Schecket al.; Developmental Medicine & Child Neurology; Mar. 2012; pp. 684-695.
Pharmacotherapy of Spasticity in Children with Cerebral Palsy; Verrotti et al; Elsevier, Inc. 2006; pp. 1-6.
Speech and Language Therapy for Children with Cerebral Palsy . . . US National Library of Medicine; Jul. 21, 2006; pp. 1-2
Intensive Speech and Language Therapy for Older Children..Cerebral Palsy . . . ; Pennington et al.; Developmental Medicine & Child Neurology; Apr. 2009; pp. 337- 344.
Dopamine Treatment in Children with Cerebral Palsy; Shaare Zedek Medical Center; NIH; May 2011; pp. 1-3.
Perceptual and Articulatory Changes in Speech Production . . . Maria I. Griogs, Ph.D., et al.; J. Med. Speech Language Pathol. 2012; 18(4); pp. 46-53.
Speech Problems Affect More Than one in Two Children With Cerebral Palsy . . . A. Nordberg et al.;ACTA Paediatrica; 2012; pp. 161-166.
Speech, Expressive Language, and Verbal Cognition . . . with Cerebral Palsy in Iceland; Developmental Medicine & Child Neurology; Jul. 2010; Solveig et al.; pp. 74-80.
Oromotor Variability in Children with Mild Spastic Cerebral Palsy . . . ; Journal of Neuroengineering and Rehabilitation: 2010; Chia-Ling Chen, et al.; pp. 1-10.
Oromotor Dysfunction and Communication Impairments in Children with Cerebral Palsy . . . ; Parkes, et al.; Developmental Medicine & Child Neurology; Jun. 2010; pp. 1113-1119.
Long-Term Survival for a Cohort of Adults with Cerebral Palsy; Hemming Ph.D., et al.; Developmental Medicine & Child Neurology; 2006; 48: pp. 90-95.

(Continued)

Primary Examiner — Kevin E Weddington

(74) Attorney, Agent, or Firm — Marvin Feldman; Lackenbach Siegel, LLP

(57) **ABSTRACT**

A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.